Raj Denhoy Biography and Net Worth

Chief Financial Officer of Establishment Labs

Mr. Denhoy has been part of Establishment Labs^® since February 2021. Prior to becoming CFO in December 2021, he served as the company’s Head of Strategy and Investor Relations. He joined the company from Jefferies Group, LLC where he worked as Managing Director and led the U.S. medical device research team for 11 years, including coverage of Establishment Labs^®. He covered the medical device industry as an equity research analyst for over 20 years. Mr. Denhoy has a bachelor’s degree in Biology from UC Berkeley, a master’s degree in Physiology from Georgetown University, and an MBA from Cornell University.

What is Raj Denhoy's net worth?: The estimated net worth of Raj Denhoy is at least $487.60 thousand as of November 17th, 2023. Mr. Denhoy owns 8,112 shares of Establishment Labs stock worth more than $487,604 as of April 10th. This net worth estimate does not reflect any other investments that Mr. Denhoy may own. Learn More about Raj Denhoy's net worth.
How do I contact Raj Denhoy?: The corporate mailing address for Mr. Denhoy and other Establishment Labs executives is Building B15 and 25 Coyol Free Zone, Alajuela G2, . Establishment Labs can also be reached via phone at (062) 434-2400 and via email at [email protected]. Learn More on Raj Denhoy's contact information.
Has Raj Denhoy been buying or selling shares of Establishment Labs?: Raj Denhoy has not been actively trading shares of Establishment Labs during the past quarter. Most recently, on Friday, November 17th, Raj Denhoy bought 2,250 shares of Establishment Labs stock. The stock was acquired at an average cost of $22.21 per share, with a total value of $49,972.50. Following the completion of the transaction, the chief financial officer now directly owns 8,112 shares of the company's stock, valued at $180,167.52. Learn More on Raj Denhoy's trading history.
Who are Establishment Labs' active insiders?: Establishment Labs' insider roster includes Juan Chacon (CEO), Juan Chacon-Quiros (Founder), Dennis Condon (Director), Roberto de Mezerville (CTO), Raj Denhoy (CFO), Raj Denhoy (Chief Financial Officer), Renee Gaeta (CFO), Lisa Gersh (Director), Nicholas Lewin (Director), and Edward Schutter (Director). Learn More on Establishment Labs' active insiders.
Are insiders buying or selling shares of Establishment Labs?: During the last twelve months, insiders at the sold shares 2 times. They sold a total of 37,500 shares worth more than $2,263,516.75. The most recent insider tranaction occured on March, 25th when Director Quiros Juan Jose Chacon sold 3,575 shares worth more than $214,786.00. Insiders at Establishment Labs own 11.1% of the company. Learn More about insider trades at Establishment Labs.
Information on this page was last updated on 3/25/2026.

Raj Denhoy Insider Trading History at Establishment Labs

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/17/2023	Buy	2,250	$22.21	$49,972.50	8,112

Raj Denhoy Buying and Selling Activity at Establishment Labs

Establishment Labs Company Overview

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Today's Range

Now: $60.19

$59.94

$62.63

50 Day Range

MA: $67.43

$54.69

$79.67

2 Week Range

Now: $60.19

$28.67

$83.31

Volume

354,544 shs

Average Volume

470,817 shs

Market Capitalization

$1.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08